pipette
ESEspañol

Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial

Zhihao Lu, Zhangzhou Huang, X. Meng, Yun Fan, Tao Wu, Qingsong Pang, Feng Wang, Yanqiao Zhang, Shegan Gao, Tianshu Liu, Jin Zhou, Yong Fang, Ning Li, Wei Li, Guochun Cao, Shoubing Zhou, Na Li, Feng Ye, Yinghua Ji, Jingdong Zhang, Xuwei Cai, Jianping Xiong, Mingjun Zhang, Lixin Wan, Yanhong Gu, Hui Luo, Xiaotian Zhang, Jinglei Qu, Wenhui Yang, Jianzhong Cao, Xueqiang Zhu, Jiayan Chen, Tienan Yi, Yongli Gao, Jiangqiong Huang, Zhenhua Liu, Jun Wang, Fang Ma, Yan Luo, Xuelei Ma, Jianfei Fu, Shubo Ding, Yu Liu, Sa Xiao, Hai Zhu, Yi Zhu, Lin Shen, PANKU-Esophagus01 Investigators, Yueyin Pan, Shouguo Li and 10 more

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Conclusions and Relevance Izalontamab brengitecan significantly improved PFS and OS vs chemotherapy in patients with recurrent or metastatic ESCC whose disease had progressed after first-line treatment.

Appeared: Saturday, November 14. JAMA. Peer-reviewed journal.

DOI: 10.1001/jama.2026.20250